Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Ashish Srinivasan"'
Autor:
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and
Externí odkaz:
https://doaj.org/article/c6f1e2d43a834509bfe7e3af4a9f737f
Publikováno v:
JGH Open, Vol 7, Iss 12, Pp 1012-1015 (2023)
Abstract Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage rena
Externí odkaz:
https://doaj.org/article/854f3dd6b2274409b50caea80e26b2a0
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Introduction: Anti-tumor necrosis factor (TNF) dose intensification represents an effective method of overcoming secondary loss of response (LOR); however, a subset of patients may not respond (tertiary non-response), or fail to demonstrate durable r
Externí odkaz:
https://doaj.org/article/37ee4b245206488a8597b36532a10d47
Publikováno v:
Journal of Gastroenterology and Hepatology. 38:724-732
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cd1b80d67292324fabb226bcdee83c6
https://doi.org/10.1111/jgh.16133
https://doi.org/10.1111/jgh.16133
Publikováno v:
BioDrugs. 36:639-644
Despite growing awareness of the nocebo effect, few studies have evaluated the nocebo effect using combined assessment of patient-reported outcome measures (PROMs), clinical indices, and objective biomarkers in inflammatory bowel disease (IBD) patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0f6be251cd99358375b9a907687b7f
https://doi.org/10.1007/s40259-022-00548-4
https://doi.org/10.1007/s40259-022-00548-4
Autor:
Adam R Peterson, Ashish Srinivasan, David Proud, Louise Jackett, Paul Gow, Peter De Cruz, Matthew C Choy
Publikováno v:
Inflammatory bowel diseases. 28(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e835871a873c2d5e262aae1d5e7a06ee
https://pubmed.ncbi.nlm.nih.gov/35289846
https://pubmed.ncbi.nlm.nih.gov/35289846
Autor:
Ashish Srinivasan, Daniel R. van Langenberg, Lena Thin, Yoon-Kyo An, Sherman Picardo, Jakob Begun, Shankar Menon, Simon Ghaly, Craig Haifer
Publikováno v:
Medical Journal of Australia. 214:128-133
Objective To examine whether non-medical switching of patients with inflammatory bowel disease (IBD) from originator infliximab to a biosimilar (CT-P13, Inflectra) is safe and clinically non-inferior to continued treatment with originator infliximab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64a0c781ec7f6a465d6884def9d3a7d1
https://doi.org/10.5694/mja2.50824
https://doi.org/10.5694/mja2.50824
Autor:
Ashish Srinivasan, Robert D. Little, Miles P. Sparrow, Daniel R. van Langenberg, Peter De Cruz, Mark G. Ward
Publikováno v:
Alimentary Pharmacology & Therapeutics. 51:1342-1352
BACKGROUND Virtual clinics represent a novel model of care in inflammatory bowel disease. Their effectiveness in promoting high quality use of biologic therapy and facilitating a treat-to-target approach is unknown. AIM To evaluate clinical and proce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b0f38b3c30c3560ab1d82120942931
https://doi.org/10.1111/apt.15742
https://doi.org/10.1111/apt.15742
Publikováno v:
Journal of Crohn'scolitis. 16(1)
Background and Aims Preliminary data regarding the effectiveness of tofacitinib in acute severe ulcerative colitis [ASUC] have been presented in two previous case series. We aimed to describe the novel use of high-dose tofacitinib immediately followi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb70eef18db5a111d3600e8da2a6b7f6
https://pubmed.ncbi.nlm.nih.gov/34159363
https://pubmed.ncbi.nlm.nih.gov/34159363
Publikováno v:
Inflammatory bowel diseases. 27(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38672f899a92e8217918672f07ebae25
https://pubmed.ncbi.nlm.nih.gov/33544119
https://pubmed.ncbi.nlm.nih.gov/33544119